Daphne Koller

Dec 11, 2023 | ai.nejm.org | Daphne Koller |Andrew Beam |Euan A. Ashley |Xiaoxuan Liu

Published December 11, 2023NEJM AI 2023;1(1)DOI: 10.1056/AIe2300128Large language models (LLMs) have recently emerged as a powerful tool across many areas of biomedicine. They are able to rapidly summarize large amounts of text, generate high-quality text from a short description, create code that can help support data analysis, produce images on the basis of a verbal description, and much more.

Sep 25, 2023 | a16z.com | Daphne Koller |Vijay Pande |Martin Casado |Daisy Wolf

This conversation is part of our AI Revolution series, which features some of the most impactful builders in the field of AI discussing and debating where we are, where we’re going, and the big open questions in AI. Find more content from our AI Revolution series on www.a16z.com/AIRevolution. Daphne Koller is the founder and CEO of insitro, a company using AI and machine learning to engineer drug discovery.

May 5, 2023 | beta.elsevier.com | Daphne Koller

Enabling open scienceRecent developments have the potential to enable a sea change whereby researchers from all over the world and diverse backgrounds can contribute to our scientific knowledge. However, we must be vigilant and proactive in ensuring that these tools help decrease rather than increase the gap between the haves and the have-nots, in which capabilities are available disproportionately to certain groups or deployed disproportionately to certain problem domains versus others.